Dermatology A
DLQI — Dermatology Life Quality Index
10-item patient-reported outcome measure for quality of life in skin conditions. Combined with PASI to assess biologic eligibility.
References
- Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Ciclosporin · Systemic Immunosuppressant — Eczema / Psoriasis
- Azathioprine · Systemic Immunosuppressant — Eczema / Autoimmune Dermatoses
- Salicylic Acid · Keratolytic — Warts / Psoriasis / Hyperkeratosis
- Ixekizumab · IL-17A Inhibitor — Psoriasis
- Guselkumab · IL-23 Inhibitor — Psoriasis
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.